Neuraxis Appoints New Directors, Updates Executive Contracts
Ticker: NRXS · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1933567
| Field | Detail |
|---|---|
| Company | Neuraxis, INC (NRXS) |
| Form Type | 8-K |
| Filed Date | Nov 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $5 million, $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
Neuraxis adds 2 directors, signs new deals with CEO/CFO.
AI Summary
Neuraxis, Inc. announced on November 19, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David E. Bear and Mr. David M. Miller, to its Board. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Jonathan M. Miller, and Chief Financial Officer, Mr. Michael J. Lytle, effective November 19, 2024.
Why It Matters
The election of new directors and updated executive contracts can signal strategic shifts or confidence in leadership, potentially impacting the company's future direction and investor sentiment.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance changes and executive employment agreements, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- Neuraxis, Inc. (company) — Registrant
- Dr. David E. Bear (person) — Newly Elected Director
- Mr. David M. Miller (person) — Newly Elected Director
- Dr. Jonathan M. Miller (person) — Chief Executive Officer
- Mr. Michael J. Lytle (person) — Chief Financial Officer
- November 19, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors to Neuraxis, Inc.'s Board?
Dr. David E. Bear and Mr. David M. Miller were elected as new directors to the Board of Neuraxis, Inc.
What is the effective date of the new employment agreements for the CEO and CFO?
The new employment agreements for the CEO and CFO are effective as of November 19, 2024.
What specific items are being reported in this Form 8-K?
This Form 8-K reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the state of incorporation for Neuraxis, Inc.?
Neuraxis, Inc. is incorporated in Delaware.
What is the principal executive office address for Neuraxis, Inc.?
The principal executive offices of Neuraxis, Inc. are located at 11611 N. Meridian St, Suite 330, Carmel, IN 46032.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-11-25 16:30:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value NRXS NYSE American Indi
- $5 million — gregate purchase price of approximately $5 million (the "Transaction"). Pursuant to the SP
- $250,000 — k for a purchase price of approximately $250,000. As a result of the closing of the Tr
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-24-047623.txt ( ) — 207KB
- nrxs-20241119.xsd (EX-101.SCH) — 3KB
- nrxs-20241119_lab.xml (EX-101.LAB) — 33KB
- nrxs-20241119_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 25, 2024 NEURAXIS, INC. By: /s/ Brian Carrico Name: Brian Carrico Title: President and Chief Executive Officer